Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Search
Search results
SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Look Forward – Summer 2025 – Issue 186
This edition marks the start of the charity's 50th anniversary year. It includes lots of ways to get involved over the next 12 months along with details of our Annual and Professionals' Conferences in September.
Children and young people
Different inherited sight loss conditions present noticeable symptoms at different times.
Meet a Researcher: Jing Yu
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
e-Newsletter June 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
A genetic diagnosis for RP can give rise to unexpected surprises
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Experimental therapy by Retina UK-funded researchers leads to ‘life changing improvements’
Researchers who received funding from Retina UK have carried out experimental gene therapy that is reported to have led to ‘life changing improvements’ to sight for four children with inherited sight loss.
Look Forward – Summer 2022 – Issue 177
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.